Ultrasound-activated quantum biomaterial pairs with senolytic to suppress colorectal cancer
Combining pyroptosis-inducing Pd3Sn nanostructures with the senolytic piperlongumine targets treatment-induced senescent cells and reduces metastatic tumor burden in animal models.
Advanced science (Weinheim, Baden-Wurttemberg, Germany) · Chen Z et al. · Paper published 30 Sep 2026
In animal models of subcutaneous colorectal cancer and liver metastasis, researchers tested a sequential therapy combining engineered Pd3Sn quantum biomaterials with the senolytic agent piperlongumine. Under ultrasound irradiation, the Pd3Sn nanostructures generated reactive oxygen species that initiated pyroptosis through zDHHC5-mediated S-acylation of gasdermin D. Senescence-associated secretory phenotype factors from these pyroptotic cells pushed surviving cancer cells into a senescent state. Adding piperlongumine selectively destroyed these senescent cells, curbing their pro-tumorigenic effects. Overall, this combined strategy suppressed tumor progression in the animal models, achieving an 83.4% tumor volume inhibition rate and a minimal liver metastatic burden.
Why it matters
The study demonstrates how the senescence-associated secretory phenotype can push surviving cells into senescence during therapy. It highlights how senolytics can be coupled with other interventions to clear therapy-induced senescent cells.
Caveats
The findings are limited to animal subcutaneous and liver metastasis models under specific experimental ultrasound conditions. The abstract provides no data on long-term survival or safety.
Written from the paper’s abstract, and every claim checked against it before publishing. Read the paper for the full methods and data.
The paper
Topological Quantum Biomaterials Enable Pyroptosis-Senescence Coupling for Enhanced Colorectal Cancer Therapy
Chen Z, Mei K, Yang Y et al.
Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 30 Sep 2026 · Peer-reviewed
- Relevance
- Relevant
- News value
- Notable
- Evidence
- Animals
- Status
- Peer-reviewed
More on Cellular senescence
See allDasatinib and quercetin reduce liver fibrosis in a phase-2 MASH trial
The senolytic combination improved liver fibrosis without disease worsening in nearly half of treated participants while lowering cellular senescence markers.
Nature metabolism · Koning M et al.
A distinct p21-driven macrophage senotype accumulates during aging and liver disease
Researchers identified a p53-p21-Cyclin D2 axis that governs senescent macrophages in mice and human liver cirrhosis and can be cleared with senolytics.
bioRxiv · Torres G et al.
DNA methylation proxies of senescence markers track human disease and mortality
The new blood-based tools estimate senescence gene activity to predict incident diseases, all-cause mortality, and clinical treatment responses.
medRxiv · Simpson DJ et al.
Bispecific T cell engager eliminates senescent cells in mice and nonhuman primates
Monitored by serum transaminase levels, low doses of the drug alleviated age-related pathologies without causing the hepatotoxicity seen at higher doses.
Aging cell · Deng J et al.
A deep learning score for cellular senescence predicts human mortality and disease risk
The proteomic biomarker tracked chronic illness risk in the UK Biobank and shifted following an 18-month multimodal exercise intervention.
Aging cell · Zhao S et al.